Page last updated: 2024-08-16

propafenone and citalopram

propafenone has been researched along with citalopram in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (50.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fu, Y; Gong, Q; Huang, J; Huang, Y; Li, J; Li, X; Mao, F; Wang, H; Xu, Y; You, H; Zhang, D; Zhang, H; Zhu, J1
Garcia, A1

Reviews

1 review(s) available for propafenone and citalopram

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for propafenone and citalopram

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10

    Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Cholinesterase Inhibitors; Depression; Donepezil; Drug Design; Half-Life; Humans; Ligands; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Vilazodone Hydrochloride

2022
Adverse effects of propafenone after long-term therapy with the addition of citalopram.
    The American journal of geriatric pharmacotherapy, 2008, Volume: 6, Issue:2

    Topics: Accidental Falls; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Dizziness; Drug Interactions; Female; Humans; Propafenone; Selective Serotonin Reuptake Inhibitors

2008